Earnings call transcript: Canopy Growth posts Q1 2026 EPS beat, shares rise
Canopy Growth reported fiscal Q1 results, with adjusted EPS loss of 5.8 cents versus a 7.76-cent loss expected, and revenue of $82.2 million versus $82.29 million forecast. Net revenue rose 13% YoY to CAD 81.2 million, adjusted gross margin improved to 31%, and adjusted EBITDA loss narrowed to CAD 3.2 million. Shares rose 3.01% to $1.37 premarket.
How this was made
The 30-second read
Why it matters
This quarter’s EPS beat and gross margin expansion are the immediate catalysts, while management’s fiscal 2027 positive adjusted EBITDA target sets the next milestone for traders.
Market read
Traders are likely to reprice the probability of reaching profitability based on margin trajectory and management’s fiscal 2027 EBITDA target, while monitoring cash burn and reimbursement headwinds.
What to watch
Operating cash outflow (CAD 25 million) and the 29% Veterans Affairs Canada reimbursement reduction could outweigh margin gains if they worsen in subsequent quarters.
Background
Canopy Growth is in a turnaround under CEO Luc Mongeau, with emphasis on MTL Cannabis integration, cultivation improvements, and cost control.
Ticker impact
Canopy Growth reported an adjusted loss of 5.8 cents per share, narrower than expected, and guided to positive adjusted EBITDA in fiscal 2027.
Bias toward continued upside follow-through if investors focus on margin trajectory and fiscal 2027 EBITDA path; downside risk if reimbursement and cash burn reassert.
The article cites a quantified EPS beat, gross margin expansion to 31%, and a stated track record toward positive adjusted EBITDA, but also highlights ongoing losses and a specific reimbursement-rate headwind.
Market effects
Margin improvement and integration benefits reinforce the market narrative that cost discipline and execution are key differentiators in pressured cannabis markets.
Canadian medical cannabis growth and reimbursement-rate risk are likely to remain focal points for Canadian cannabis equities.
Europe expansion plans and regulatory constraints (EU GMP) keep international execution risk in view for global cannabis investors.
Counterpoint
The revenue line is essentially flat versus forecast and the company still reports losses, so the stock move may fade if investors demand clearer path to sustained profitability.
Key entities
- companyCanopy Growth
Reported Q1 fiscal 2027 adjusted loss and margin improvement, and reiterated track to positive adjusted EBITDA in fiscal 2027.
- personLuc Mongeau
CEO cited broad-based year-over-year growth across business segments and momentum into fiscal 2027.
- personTom Stewart
CFO discussed execution of CAD 8 million MTL-related synergies and upside to the original synergy target.
